Y Intercept Hong Kong Ltd Has $242,000 Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Y Intercept Hong Kong Ltd decreased its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 57.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,559 shares of the company's stock after selling 39,244 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Wave Life Sciences were worth $242,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Orion Portfolio Solutions LLC acquired a new stake in Wave Life Sciences in the third quarter worth $123,000. XTX Topco Ltd acquired a new stake in shares of Wave Life Sciences in the 3rd quarter worth about $126,000. Jane Street Group LLC increased its holdings in shares of Wave Life Sciences by 33.3% in the 3rd quarter. Jane Street Group LLC now owns 142,014 shares of the company's stock worth $1,165,000 after acquiring an additional 35,472 shares during the period. Weiss Asset Management LP bought a new stake in Wave Life Sciences in the 3rd quarter valued at about $164,000. Finally, State Street Corp boosted its stake in Wave Life Sciences by 2.6% during the 3rd quarter. State Street Corp now owns 2,321,248 shares of the company's stock valued at $19,034,000 after purchasing an additional 57,822 shares during the period. Institutional investors own 89.73% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on WVE shares. Raymond James raised Wave Life Sciences from an "outperform" rating to a "strong-buy" rating and lifted their target price for the company from $13.00 to $22.00 in a research note on Wednesday, October 16th. Royal Bank of Canada lifted their price objective on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a "sector perform" rating in a research note on Monday, October 21st. JPMorgan Chase & Co. increased their target price on shares of Wave Life Sciences from $13.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, October 17th. B. Riley boosted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. Finally, Truist Financial increased their price objective on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $22.22.

Wave Life Sciences Trading Up 0.8 %

NASDAQ WVE traded up $0.10 during trading on Thursday, reaching $13.19. 902,567 shares of the company's stock were exchanged, compared to its average volume of 1,105,320. Wave Life Sciences Ltd. has a fifty-two week low of $3.50 and a fifty-two week high of $16.74. The company's fifty day simple moving average is $14.23 and its 200-day simple moving average is $8.93. The firm has a market capitalization of $2.01 billion, a PE ratio of -11.88 and a beta of -1.21.

Insider Transactions at Wave Life Sciences

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the firm's stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company's stock, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Paul Bolno sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $15.00, for a total value of $750,000.00. Following the transaction, the chief executive officer now owns 217,351 shares in the company, valued at approximately $3,260,265. This trade represents a 18.70 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 453,690 shares of company stock valued at $6,425,883. 29.10% of the stock is owned by insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.